Stratec SE is a listed company. Its insiders report their share dealings to BaFin. The last twelve months, up to 18 October 2026, brought 3 filings signed by 2 insiders.
No open-market purchase or sale appears among the filings, only grants, plan transactions and other operations. Because grants and exercises are largely decided by remuneration plans, they are not counted as purchases here.
For context, the typical company on the same exchange (median of 287 companies) published 5 filings over the same period, against 3 filings here.
Over the last twelve months, not one insider purchase of Stratec SE stock was filed. Typically, a trade is published a median of 2 days after it takes place. For comparison, MAR article 19 gives managers three business days to notify a trade.
This summary is built from BaFin disclosures alone and does not predict where the share price will go.
Analysts rate Stratec SE Buy (bullish), based on 5 analysts. Average price target: €25.60.
Transparent value + quality ranking, distinct from the insider signal.
FY ended December 2025 · cache
3 of 3 declarations
Stratec SE is a company specializing in the development and manufacturing of analysis systems for the healthcare sector. It is listed on the Frankfurt Stock Exchange (XETR).